Pharmafile Logo
Pharmafocus logo
Advanced Search

imbruvica

Showing 15 posts of 31 posts found.

janssen_latest_logo_on_sign_closer

Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia

December 7, 2020
Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica

Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …

News
janssen_latest_logo_on_sign

Janssen’s Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia

September 7, 2020
Sales and Marketing Europe, Janssen, imbruvica, pharma

The European Commission (EC) has moved to expand the existing approval of Janssen’s Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) …

News
abbvie_0

AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod

April 22, 2020
Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia

AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …

News
janssen_latest_logo_on_sign_closer

Janssen chalks up two more indications in Europe for Imbruvica combo therapies

August 14, 2019
Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …

News
janssen_latest_logo_on_sign

Janssen secures two positive CHMP opinions for Imbruvica label expansions

July 1, 2019
Sales and Marketing CHMP, EMA, Europe, Janssen, imbruvica, pharma

Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human …

News

Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia

January 29, 2019
Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma

It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …

News
nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News
janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

News
janssen_latest_logo_on_sign_closer

Scotland recommends Janssen’s Imbruvica for leukaemia

April 11, 2017
Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia

Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …

News
imbruvica_logo_0

NICE approves Imbruvica for second-line leukaemia treatment

January 26, 2017
Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica

NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …

News

J&J’s Imbruvica scores fifth FDA lymphoma approval

January 20, 2017
Medical Communications, Research and Development, Sales and Marketing FDA, Marginal Zone Lymphoma, imbruvica

Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone …

News
imbruv_pack

Janssen reveals positive results from longest follow-up of Imbruvica

December 7, 2016
Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica

Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …

News
nice_aerial

Lowered price wins NICE approval for Janssen leukaemia treatment

November 25, 2016
Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica

After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …

News
janssen_latest_logo_on_sign

NICE knocks back Janssen rare disease drug

October 13, 2016
Medical Communications Janssen, NICE, imbruvica

NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …

News

NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund

August 18, 2016
Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica

NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024